Señales en vivo de MITRA.BR | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:35):

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally...

Stats
Volumen de hoy	82 368.00
Volumen promedio	358 862
Capitalización de mercado	14.93M
EPS	€0 ( 2024-03-08 )
Próxima fecha de ganancias	( €0 ) 2024-05-30
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.150
ATR14	€0.00100 (0.46%)

Mithra Pharmaceuticals SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mithra Pharmaceuticals SA Finanzas

Annual	2023
Ingresos:	€40.16M
Beneficio Bruto:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2023
Ingresos:	€40.16M
Beneficio Bruto:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2022
Ingresos:	€67.00M
Beneficio Bruto:	€35.43M (52.89 %)
EPS:	€-1.220

FY	2021
Ingresos:	€22.67M
Beneficio Bruto:	€6.94M (30.63 %)
EPS:	€-1.114

Financial Reports:

No articles found.

Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.